This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC).
KRAS G12C mutation is present in a subset of NSCLC patients. While docetaxel is a standard chemotherapy option, JMKX001899 is an investigational, targeted therapy designed to selectively inhibit the KRAS G12C mutation. This trial aims to determine whether JMKX001899 offers a superior clinical benefit compared to standard chemotherapy.
Age ≥ 18 years.
Histologically or cytologically confirmed NSCLC.
Failure of at least one prior line of therapy for locally advanced/metastatic disease, that included a platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.
At least one measurable lesion as defined by RECIST version 1.1.
Known concomitant presence of other oncogenic driver mutations or rearrangements with established targeted therapies .
Previous treatment with any KRAS G12C-targeted agent.
Prior docetaxel therapy in the locally advanced/metastatic setting.
Parallel
JMKX001899
DrugOrally, once daily
Docetaxel
DrugBy IV infusion every 21 days
PFS
Progression-Free Survival
OS
Overall Survival
AE
Adverse Event
This trial is not recruiting at the moment. You can still explore other options:
